What the Lilly Combination Is
The headline-making treatment pairs two injectable drugs, eloralintide and tirzepatide, into a single approach called EloraTZP. The goal is to address obesity and type 2 diabetes together by targeting appetite and blood sugar through separate hormone pathways.
Tirzepatide is already sold in approved form as Mounjaro for diabetes and Zepbound for obesity. Eloralintide is a newer medicine that mimics amylin, a hormone released with insulin that helps curb hunger and slow digestion. Lilly tested the drugs together, and separately, in a 48-week phase 2 study involving 367 adults.
Why this matters: it is aimed at people living with type 2 diabetes and stubborn weight gain, the exact overlap studied in the trial.
How Tirzepatide Works
Tirzepatide activates two gut hormone receptors, GIP and GLP-1, which help signal fullness to the brain and slow stomach emptying. That dual action can reduce appetite and improve how the body uses insulin, making it useful for both diabetes and weight management.
GLP-1 alone, the mechanism behind drugs such as Ozempic, already slows digestion and helps curb hunger. Tirzepatide adds GIP activity on top of that, and that dual-hormone effect is one reason it has outperformed single-hormone drugs in comparisons. Adding eloralintide brings in a third signal that tells the brain to eat less, which helps explain the stronger results seen in the new trial.
Common misconception: tirzepatide does not work like older drugs such as metformin. It does not lower blood sugar through the liver; instead, it works through appetite and digestion, which is why weight loss and better glucose control often occur together.
How It Compares With Ozempic
In weight-loss studies, tirzepatide-based medicines have generally beaten semaglutide, the active ingredient in Ozempic. The EloraTZP combination appears to widen that lead even more: Ozempic targets one hormone pathway, tirzepatide targets two, and EloraTZP targets three.
Here is a simple comparison based on current trial data:
Ozempic (semaglutide): GLP-1 only; up to roughly 15% weight loss in some trials; FDA approved for diabetes, with Wegovy approved for weight loss
Mounjaro/Zepbound (tirzepatide): GIP/GLP-1 dual action; about 14.8% weight loss at the 15 mg dose in a diabetes trial; FDA approved
EloraTZP (eloralintide + tirzepatide): GIP/GLP-1 plus amylin; 23.3% weight loss in the 48-week diabetes trial; still experimental
Retatrutide: triple-hormone approach; about 23% weight loss over 80 weeks in a diabetes trial; still in late-stage testing
When Ozempic may make sense: for milder blood sugar management and the longest real-world track record. When tirzepatide may make more sense: when stronger weight loss is needed and a doctor says the side effects are manageable. EloraTZP is not available outside a clinical trial.
Cost and Coverage
There is no public price for EloraTZP because it is not approved or sold commercially. Existing tirzepatide products, Mounjaro and Zepbound, usually cost more than $1,000 a month without insurance, though savings cards and coverage can lower that for eligible patients.
Cost remains a major barrier for many people. Insurance coverage can differ sharply depending on whether the drug is prescribed for diabetes or for weight loss, and some plans cover tirzepatide for diabetes but not for weight management alone.
Coverage wrinkle: some patients need documentation of another condition, such as high blood pressure or sleep apnea, to get weight-loss coverage approved.
FDA Status
EloraTZP has not been approved by the FDA and remains an experimental phase 2 treatment. Lilly has not announced a regulatory filing, and larger phase 3 trials will be needed before approval can be considered.
Phase 2 studies test safety and effectiveness in a few hundred people before moving to much larger phase 3 trials. That process often takes years, so the 23.3% weight-loss figure should be viewed as promising early evidence rather than a treatment available now.
Important warning: any product or online pharmacy claiming to sell “EloraTZP” now should be treated as a red flag. It is not an approved drug.
Who Tirzepatide Is For
Tirzepatide, sold as Zepbound for weight loss, is approved for adults with obesity or adults who are overweight and have at least one weight-related condition such as high blood pressure, type 2 diabetes, or sleep apnea. It requires a prescription and medical supervision.
A diabetes diagnosis is not required to qualify for Zepbound, since it is separately approved for weight management. Mounjaro, by contrast, is approved specifically for type 2 diabetes. People should discuss their full medical history with a doctor before starting treatment.
Tirzepatide is generally not recommended for:
People with a personal or family history of medullary thyroid cancer
People with Multiple Endocrine Neoplasia syndrome type 2
Pregnant or breastfeeding individuals
People with severe gastrointestinal disease, unless guided by a specialist
Side Effects
The most common side effects of tirzepatide are nausea, diarrhea, vomiting, constipation and stomach discomfort, especially when starting treatment or increasing the dose. These effects are usually mild to moderate and often improve over time.
In the EloraTZP trial, adding eloralintide did not appear to create major new safety concerns beyond what is already known for amylin and GLP-1 drugs, though longer-term safety still needs to be confirmed in larger phase 3 studies. Rare but serious risks with tirzepatide include pancreatitis, gallbladder problems and kidney issues linked to dehydration from vomiting or diarrhea.
Anyone managing cardiovascular risk factors should keep their care team informed while using a weight-loss drug.
How Much Weight the Combo Produced
In the 48-week trial, the highest-dose EloraTZP regimen, 9 mg of eloralintide plus 15 mg of tirzepatide, led to average weight loss of 23.3%, or about 54 pounds, among participants with obesity and type 2 diabetes. That was nearly 8.5 percentage points more than the strongest tirzepatide-only dose, which produced about 14.8% weight loss.
The data also slightly surpassed Lilly’s other major obesity candidate, retatrutide, which has shown roughly 23% weight loss over 80 weeks in a separate diabetes trial. Blood sugar control improved as well, with A1C dropping by as much as 2.9 percentage points in the top-dose combo group, compared with 2.4 points for tirzepatide alone.
Example: a 250-pound participant in the top-dose group would, on average, be expected to lose about 58 pounds over 48 weeks.
Can People Without Diabetes Use It?
People without diabetes can use tirzepatide only through Zepbound, not through EloraTZP. Zepbound is approved for weight loss in people who meet the BMI and health-condition criteria. EloraTZP itself has only been studied in people with type 2 diabetes.
It is not yet known whether EloraTZP would work the same way in people without diabetes, because fat and blood sugar metabolism differ between those groups. Future research would likely be needed before any approval for non-diabetic patients could be considered.
Mounjaro vs. EloraTZP
Mounjaro and Zepbound both contain tirzepatide, but they are approved for different uses. Mounjaro is for type 2 diabetes, while Zepbound is for chronic weight management. EloraTZP is a separate, unapproved combination that adds eloralintide to tirzepatide.
Mounjaro: tirzepatide; approved for type 2 diabetes
Zepbound: tirzepatide; approved for chronic weight management
EloraTZP: eloralintide plus tirzepatide; still in phase 2 testing
Use Mounjaro if: blood sugar control is the main goal. Use Zepbound if: weight loss is the primary goal and you meet the criteria. Neither is EloraTZP, which remains trial-only.
How Quickly Results Appear
Most people on tirzepatide-based treatment begin noticing appetite changes within a few weeks, while measurable weight loss usually builds over three to six months as the dose increases. In the EloraTZP trial, the full 23.3% average weight loss was measured at 48 weeks, not right away.
These medications are typically started at a low dose and increased gradually to reduce nausea and other digestive side effects. People who stop too early, before reaching a maintenance dose, often see less weight loss than the trial results suggest.
Note: quick early loss does not mean it is safe to stop treatment. Doctors often advise staying on an effective dose long term, because weight can return after stopping.
Common Injection Mistakes
Frequent mistakes include inconsistent dosing, failing to rotate injection sites and skipping doses without medical guidance. These habits can reduce effectiveness or worsen side effects.
Other common errors include:
Using the same small area repeatedly, which can cause irritation or uneven absorption
Eating a large high-fat meal soon after dosing, which may worsen nausea
Not drinking enough water, which can raise the risk of dehydration-related kidney strain
Expecting results without changing diet or activity
Stopping abruptly because of side effects instead of talking with a doctor about dose changes
Why It May Not Seem to Work
If a GLP-1 or tirzepatide drug does not seem effective, common reasons include too low a dose, inconsistent timing, eating habits that work against the treatment or another medical problem that needs separate attention. A doctor can often sort this out with bloodwork and a dose review.
Some people simply respond more slowly and need more time at a given dose before increasing it. Even in controlled trials, individual results varied widely around the average, so not everyone reaches the headline numbers.
When to call the doctor: if weight loss stalls for more than four to six weeks at a stable dose, a follow-up is reasonable rather than assuming the medicine failed.
Frequently Asked Questions
Is EloraTZP the same as Zepbound or Mounjaro?
No. EloraTZP is an experimental combination of eloralintide and tirzepatide. Zepbound and Mounjaro contain only tirzepatide.
When will EloraTZP be available?
There is no confirmed timeline. It still needs phase 3 trials and FDA review.
Does it cure type 2 diabetes?
No. It may improve blood sugar control and support major weight loss, but it is a treatment, not a cure.
How does it compare with retatrutide?
Retatrutide has shown about 23% weight loss over 80 weeks in a diabetes trial. EloraTZP showed 23.3% over 48 weeks.
Can I get it through my doctor now?
No. It is only available in clinical trials.
Is weight regain common after stopping these drugs?
Yes. Weight regain is a known risk when GLP-1 or GIP-based drugs are stopped.
Does insurance cover tirzepatide for weight loss?
Coverage varies widely, and some plans cover it for diabetes but not for weight management.
Key Points
EloraTZP combines eloralintide, an amylin mimic, with tirzepatide.
The highest-dose combination produced 23.3% average weight loss, about 54 pounds, in a 48-week trial.
Tirzepatide alone produced about 14.8% weight loss in the same study.
Blood sugar control improved more with the combination than with either drug alone.
The study included 367 adults with obesity or overweight plus type 2 diabetes.
EloraTZP remains experimental and has not been submitted for FDA approval.
Common side effects include nausea, vomiting and digestive discomfort.
People without diabetes may eventually access tirzepatide through Zepbound, but EloraTZP is not available yet.
Bottom Line
Eli Lilly’s EloraTZP study marks a meaningful advance for two conditions that often feed into each other: obesity and type 2 diabetes. The 23.3% average weight loss and improved blood sugar control reported in this 48-week trial give doctors and patients reason for optimism.
Still, the treatment is not ready for routine use. The practical next step is to talk with a primary care doctor or endocrinologist about what is available now, including Mounjaro, Zepbound or other approved options that fit a person’s health needs and budget. Questions about dosing, side effects and insurance should be addressed before starting any treatment.
For readers weighing these choices, local clinics and community health resources can be a useful starting point. For now, EloraTZP should be watched as an experimental drug, not a product on pharmacy shelves.
More from Digilifetrends
How I Took Charge of My Weight Loss Journey
The following story was sponsored by Novo Nordisk. Heath McFarland is a real Wegovy ® patient and a paid spokesperson for Novo Nordisk.
13 min read · Updated 2026-10-08The Seven-Day Fat Flush Soup Challenge Helps Rein in Cravings and Kick Off Weight Loss
When the air turns cooler, it can be easy to slip out of healthy routines and lean into comfort foods. But this season, you can enjoy soup and still support weight loss. The…
4 min read · Updated 2026-10-08How GLP-1 Weight-Loss Drugs Are Reshaping Food and Drink
GLP-1 drugs are no longer a niche topic for the food and beverage industry.
6 min read · Updated 2026-10-08